Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients

Sponsor
Dan Liang
Study ID
NCT05155592
Phase
PHASE2
Status
Unknown

Conditions

  • Adalimumab
  • Uveitis

Eligibility Criteria

Sex
ALL
Age
2 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • reduction or discontinuation of Adalimumab — BIOLOGICAL
    For patients with non-infectious uveitis whose inflammation stabilizes after treated with Adalimumab, extended dosing intervals to once a month, during which inflammatory status is monitored. If there was no recurrence within 6 months, Adalimumab was discontinued, and whether inflammation recurred after withdrawal was observed.

Study Details

TNF-α inhibitors, like Adalimumab, have good efficacy in non-infectious uveitis, but long-term use can increase the risk of drugs, and the patient's financial burden is large. The objective of this study was to explore the reduction or withdrawal of Adalimumab in uveitis patients with stable drug control, and to evaluate the efficacy and safety of drug reduction in uveitis patients, as well as the impact on their vision prognosis.

Key Dates

Start date
Jan 1, 2021
Status verified
Dec 2021
Primary completion
Jan 1, 2023
Completion
Apr 1, 2023

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Patients with inactive uveitis
    Patients with non-infectious uveitis whose inflammation reached remission for at least six months after treatment with Adalimumab

Primary Outcome Measure

relapse rate of inflammation [ Time Frame: 24 months ]

Central Contacts

Related Studies